Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 8, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1147

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1117–1128 of 1,147 matching trials for Lung Cancer.

Indexed local directory records.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search

Conditions: Non-small Cell Lung Cancer Metastatic
Interventions: Predictive models (data collection); Other
Lead sponsor: Sophia Genetics SAS; Industry
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Iowa City, Iowa • Worcester, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Lung Cancer
Interventions: Afatinib, Cisplatin, Pemetrexed, Radiation, Surgery; Drug · Radiation · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer With A High Tumor Mutational Burden, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Extensive-stage Small-cell Lung Cancer, Fallopian Tube Cancer, MSI-H Cancer, Neuroendocrine Tumors, Primary Peritoneal Carcinoma, Solid Tumor
Interventions: 23ME-00610; Drug
Lead sponsor: 23andMe, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more

Conditions: Cancer, Carcinoma, MSI-High, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumor, Squamous Cell Carcinoma of the Head and Neck, Triple-negative Breast Cancer
Interventions: Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], ST-067, pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Lung Cancer, Pulmonary Nodule, Solitary
Interventions: Not listed
Lead sponsor: Veracyte, Inc.; Industry
Eligibility: 29 Years to 85 Years
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Hartford, Connecticut • Stamford, Connecticut • Bay Pines, Florida + 19 more

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Non-small Cell Lung Cancer
Interventions: [18F]F-ARAG PET; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Cemiplimab, Computed Tomography, Fludeoxyglucose F-18, Ipilimumab, Nab-paclitaxel, Nivolumab, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan; Biological · Procedure · Drug + 2 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bladder Urothelial Cancer, Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colorectal Carcinoma, Endocervical Cancer, Esophageal Cancer, Gastric Cancer, Melanoma, Mesothelioma, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Interventions: NGM831, NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®), NGM831 plus pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more

Conditions: Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colorectal Cancer, Endocervical Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma, Melanoma, Mesothelioma, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Interventions: NGM707, NGM707 plus pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more

Conditions: Lung Cancer
Interventions: Chest X-ray Tomosynthesis; Diagnostic Test
Lead sponsor: University of California, San Diego; Other
Eligibility: 30 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lung Cancer
Interventions: Salaso Virtual Exercise Program; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Hyde Park, New York

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Stored official records

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Afatinib With CT and RT for EGFR-Mutant NSCLC

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Test-retest Evaluation of [18F]F-AraG PET

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Next Generation Chest X-Ray Tomosynthesis for Screening of Lung Cancer

Virtual Personalized Exercise Program for Lung Cancer Patients

About this Lung Cancer clinical trials directory page